Corbus Pharmaceuticals (CRBP) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genelux (GNLX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 47.4% versus a loss of 60.7%. Genelux is the larger company by market cap ($114.9 million vs $102.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | GNLX |
|---|---|---|
| Share price | $5.32 | $2.54 |
| Market cap | $102.90M | $114.92M |
| 1-day change | +0.95% | +1.60% |
| YTD return | -35.26% | -42.66% |
| 1-year return | -60.73% | -47.37% |
| 5-year return | -82.78% | — |
| EPS (TTM) | $-6.11 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $8.54 |
| 52-week low | $5.13 | $2.29 |
| Distance from 52-week high | -74.12% | -70.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +539.66% | +641.34% |
| Average volume | 756.54K | 276.16K |
| Shares outstanding | 19.34M | 45.25M |
| Employees | 36 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed CRBP by 13.4 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
CRBP vs GNLX FAQ
Which is bigger, Corbus Pharmaceuticals or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $114.92M compared with $102.90M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, CRBP or GNLX?
GNLX returned -47.37% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.